Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor

被引:20
|
作者
Batley, BL
Doherty, AM
Hamby, JM
Lu, GH
Keller, P
Dahring, TK
Hwang, O
Crickard, K
Panek, RL
机构
[1] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Therapeut, Ann Arbor, MI 48105 USA
[2] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Chem, Ann Arbor, MI 48105 USA
[3] SUNY Coll Buffalo, Dept Obstet & Gynecol, Buffalo, NY 14222 USA
关键词
FGF-1 receptor tyrosine kinase; PD; 161570; tyrosine phosphorylation; angiogenesis;
D O I
10.1016/S0024-3205(97)01060-6
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Through direct synthetic efforts we discovered a small molecule which is a 40 nanomolar inhibitor of the human FGF-1 receptor tyrosine kinase. 1-Tert-butyl-3-[6-(2,6-dichloro-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD 161570) had about 5- and 100-fold greater selectivity toward the FGF-I receptor (IC50 = 40 nM) compared with the PDGF beta receptor (IC50 = 262 nM) or EGF receptor (IC50 = 3.7 mu M) tyrosine kinases, respectively. In addition, PD 161570 suppressed constitutive phosphorylation of the FGF-I receptor in both human ovarian carcinoma cells (A121(p)) and Sf9 insect cells overexpressing the human FGF-1 receptor and blocked the growth of A121(p) cells in culture. The results demonstrate a novel synthetic inhibitor with nanomolar potency and specificity towards the FGF-T receptor tyrosine kinase.
引用
收藏
页码:143 / 150
页数:8
相关论文
共 50 条
  • [1] In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase
    Panek, RL
    Lu, GH
    Dahring, TK
    Batley, BL
    Connolly, C
    Hamby, JM
    Brown, KJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 286 (01): : 569 - 577
  • [2] USE OF ERBSTATIN AS PROTEIN-TYROSINE KINASE INHIBITOR
    UMEZAWA, K
    IMOTO, M
    METHODS IN ENZYMOLOGY, 1991, 201 : 379 - 385
  • [3] Tec protein-tyrosine kinase is an effector molecule of Lyn protein-tyrosine kinase
    Mano, H
    Yamashita, Y
    Miyazato, A
    Miura, Y
    Ozawa, K
    FASEB JOURNAL, 1996, 10 (05): : 637 - 642
  • [4] Inhibition of neurotransmitter release by protein-tyrosine kinase
    Ohnishi, H
    Yamamori, S
    Hirata, K
    Aoyagi, K
    Kondo, S
    Takahashi, M
    JOURNAL OF NEUROCHEMISTRY, 2001, 78 : 199 - 199
  • [5] INHIBITION OF PROTEIN-KINASE-C AND PROTEIN-TYROSINE KINASE BY SILYBINS
    CHANG, SC
    CHEN, DH
    ASHENDEL, CL
    GEAHLEN, RL
    CHAN, CJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 209 : 52 - MEDI
  • [6] NEW INSIGHTS INTO PROTEIN-TYROSINE KINASE RECEPTOR SIGNALING COMPLEXES
    FRY, MJ
    PANAYOTOU, G
    BOOKER, GW
    WATERFIELD, MD
    PROTEIN SCIENCE, 1993, 2 (11) : 1785 - 1797
  • [7] INHIBITION OF CRYSTAL-INDUCED NEUTROPHIL ACTIVATION BY A PROTEIN-TYROSINE KINASE INHIBITOR
    BURT, HM
    JACKSON, JK
    SALARI, H
    JOURNAL OF LEUKOCYTE BIOLOGY, 1994, 55 (01) : 112 - 119
  • [8] Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
    Heinrich, MC
    Griffith, DJ
    Druker, BJ
    Wait, CL
    Ott, KA
    Zigler, AJ
    BLOOD, 2000, 96 (03) : 925 - 932
  • [9] EFFECTS OF PROTEIN-TYROSINE KINASE INHIBITORS ON EGG ACTIVATION AND FERTILIZATION-DEPENDENT PROTEIN-TYROSINE KINASE-ACTIVITY
    MOORE, KL
    KINSEY, WH
    DEVELOPMENTAL BIOLOGY, 1995, 168 (01) : 1 - 10
  • [10] Inhibition of obliterative bronchiolitis by platelet-derived growth factor receptor protein-tyrosine kinase inhibitor
    Kallio, E
    Koskinen, P
    Buchdunger, E
    Lemström, K
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) : 187 - 187